By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Myriad Genetics, Inc. 

320 Wakara Way

Salt Lake City  Utah  84108  U.S.A.
Phone: 801-584-3600 Fax: 801-584-3640


Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.


May 1991


CEO and Founder: Mark Capone

CMO (Medical): Richard Wenstrup

CFO: Bryan Riggsbee

CSO (Scientific): Jerry Lanchbury


Please click here for Myriad Genetics job opportunities.


Please click here for clinical trial information.


All Products


Key Statistics

Ownership: Public

Web Site: Myriad Genetics
Symbol: MYGN

Company News
Myriad Genetics (MYGN) Forms Relationship With ION Solutions To Deliver Quality Hereditary Cancer Tests And Services To The Nation's Largest Network Of Community Oncologists 10/21/2016 10:24:21 AM
Myriad Genetics (MYGN) Teams Up With Project BioEYES To Advance STEM Education In Utah 10/18/2016 8:16:05 AM
Myriad Genetics (MYGN) Will Present New Data On Its Variant Classification Program At The ASHG Annual Meeting 10/17/2016 7:11:29 AM
Tesaro (TSRO) Attempts to Squash Partner Myriad Genetics (MYGN)’ Contrary Press Release Over Niraparib 10/14/2016 6:44:18 AM
Myriad Genetics (MYGN)’s Mychoice HRD Test Identifies Patients With Ovarian Cancer Who May Benefit From Treatment With Niraparib 10/10/2016 8:23:07 AM
Myriad Genetics (MYGN) Announces Four Poster Presentations At The 2016 European Society For Medical Oncology (ESMO) Annual Meeting 10/7/2016 6:50:27 AM
The US Oncology Network Network Selects Myriad Genetics (MYGN) As Preferred Provider For Hereditary Cancer Testing 10/4/2016 7:51:20 AM
Myriad Genetics (MYGN) Appoints Chip Parkinson As EVP For Reimbursement Strategy 9/29/2016 7:43:56 AM
Myriad Genetics (MYGN) To Present New Myrisk Hereditary Cancer Data Further Demonstrating The Benefits Of Gene Panel Testing 9/26/2016 7:41:13 AM
Myriad Genetics (MYGN) Completes Acquisition Of Assurex Health 9/2/2016 7:28:18 AM